Fig. 4

Inhibition of PcG complex sensitizes HCC cells to chemotherapy. A Cell viability of HCC cells under treatment of oxaliplatin together with GSK126 or PRT4165. The signal from three independent wells were collected and 50% inhibitory concentration (IC50B) was calculated by four-parameter model. B Cell apoptosis rate of HCC cell after oxaliplatin treatment (5 μg/ml) with GSK126 or PRT4165 measured by flow cytometry. Ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.005; ****p < 0.001. C Huh7-cell derived subcutaneously tumor after treatment of oxaliplatin with or without GSK126 and PRT4165. ***p < 0.005; ****p < 0.001. D The IHC assay of γH2A.X and Ki67 subcutaneously tumor after low-dose oxaliplatin treatment with or without GSK126 and PRT4165. The black bar represents 100 μm, and *p < 0.05; ***p < 0.005